EAU 2021 | CheckMate 274: adjuvant nivolumab versus placebo for urothelial carcinoma
Matthew Galsky, MD, FASCO, Icahn School of Medicine at Mount Sinai, New York, NY, gives an update on the Phase III CHeckMate 274 trial (NCT02632409) which is investigating adjuvant nivolumab versus placebo in patients with bladder or upper urinary tract cancer who have previously received surgical treatment for removal of the cancer. Prof. Galsky reports that adjuvant nivolumab was found to be associated with a significant improvement in disease-free survival with no detriment to quality of life. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.
Disclosures
Matthew Galsky, MD, FASCO, has a stock or other ownership interest in Rappta Therapeutics; has participated in a consulting or advisory role for BioMotiv, Janssen, Dendreon, Merck, GSK, Lilly, Astellas Pharma, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, Dragonfly Therapeutics, Basilea, Urogen, Infinity Pharmaceuticals and Gilead; and has received research funding from Janssen Oncology, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca and Genentech/Roche.
